List view / Grid view
12 February 2015 | By KU Leuven
Writing in the journal EBioMedicine, researchers at KU Leuven’s Laboratory for Clinical and Epidemiological Virology now report a recombinant form of HIV observed in patients in Cuba that makes this transition much faster...
11 February 2015 | By Eli Lilly & Company
College freshmen face tremendous pressure, often trying to adjust to tough academic standards while living away from home for the first time...
Amazing opportunities come along with prototyping technologies, and three-dimensional (3D) printing is gaining momentum across various industries, from printing a mobile phone cover to reconstructing human organs. Emerging as a technology of choice for a wide range of applications, 3D printing is expected to increase its market share rapidly to…
11 February 2015 | By GlobalData
Following a less than flattering financial performance in 2014, GlaxoSmithKline plc is realigning its operating structure with its corporate objectives and cashing in on its assets in the process, as the company seeks to drive up external investments and deliver stronger shareholder returns in the long term, says an analyst…
10 February 2015 | By kdm communications
Re-Pharm, an early-stage drug discovery and development company based on the principles of compound re-profiling, is pleased to announce the identification of RP0217 as an effective new anti-inflammatory agent...
10 February 2015 | By kdm communications
Microfluidics specialist Dolomite has created a low cost kit aimed at educational initiatives or those new to microfluidics...
10 February 2015 | By Boehringer Ingelheim
Boehringer Ingelheim, a research-based, global pharmaceutical company, and VTU Technology, a leading contract research and development company, announced today the renewal of their global Pichia pastoris technology collaboration agreement...
10 February 2015 | By Doctors of the World
Doctors of the World - Médecins du Monde is today filing its opposition to the patent granted for sofosbuvir (Sovaldi) with the European Patent Office...
10 February 2015 | By The Institute of Cancer Research
Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said: “We’re very disappointed that Scottish men with prostate cancer will miss out on the chance to have abiraterone much earlier in their course of treatment as a result of this decision..."
9 February 2015 | By Pharmaceutical Licensing Group
Pharmaceutical Licensing Group has announced the results of its 8th Annual Awards for excellence in business development which were given at its AGM on 5th February 2015...
9 February 2015 | By Alkermes plc
Alkermes plc announced positive topline results from a phase 1, randomized, double-blind clinical study of ALKS 8700, a novel monomethyl fumarate (MMF) molecule in development for the treatment of multiple sclerosis...
9 February 2015 | By Eli Lilly and Company
Eli Lilly and Company will present at the 2015 Leerink Global Healthcare Conference on Wednesday, February 11, 2015. Alfonso Zulueta, Sr. Vice President and President, Emerging Markets will participate in a fireside chat at 8:25 a.m. EST...
9 February 2015 | By GlobalData
Adam Dion, MS, GlobalData’s Healthcare Industry Analyst, says: “On 5 February 2015, just days after gaining US Food and Drug Administration (FDA) breakthrough approval for Ibrance (palbociclib) in breast cancer, Pfizer entered into an agreement to purchase generic drug maker Hospira..."
9 February 2015 | By Roche
Roche announced that the U.S. Food and Drug Administration approved Lucentis® (ranibizumab injection) for the treatment of diabetic retinopathy, in people with diabetic macular edema...
9 February 2015 | By Moberg Pharma
Moberg Pharma AB announced that Berlin-Chemie AG, a member of the Menarini Group – a top 40 global pharmaceutical company – has been granted the exclusive rights to market and sell Emtrix® in Russia and Ukraine...
